

**From:** Do, Yu  
**To:** [Joan.robertson@grifols.com](mailto:Joan.robertson@grifols.com)  
**Subject:** Mid-Cycle Communication (MCC) Summary: MCC Teleconference, Thursday, April 27, 2017, 10 AM, EST  
**Date:** Thursday, May 11, 2017 2:24:00 PM  
**Attachments:** [BL\\_125640\\_Mid-Cycle\\_Communication\\_Summary\\_CERT.pdf](#)  
[image001.png](#)  
**Importance:** High

---

Dear Ms. Robertson:

Attached is a copy of the meeting summary for Mid-Cycle Communication that occurred on Thursday, April 27, 2017, at 10 AM.

Please acknowledge receipt of this document and contact me at (240) 402-8343 or [Yu.Do@fda.hhs.gov](mailto:Yu.Do@fda.hhs.gov) if you have any questions.

Sincerely,

Yu Do, M.S.  
Regulatory Project Manager  
Office of Tissues and Advanced Therapies  
Center for Biologics Evaluation and Research  
Office of Medical Products and Tobacco  
Food and Drug Administration  
(240) 402-8343  
[Yu.Do@fda.hhs.gov](mailto:Yu.Do@fda.hhs.gov)



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."